Prasugrel
Prasugrel, sold as Effient, is an antiplatelet medicine of the P2Y12 inhibitor class. The US label read lists one use: lowering the rate of thrombotic cardiovascular events, including stent thrombosis, in people with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI (percutaneous coronary intervention)). That covers unstable angina or non-ST-elevation heart attack, and ST-elevation heart attack managed with primary or delayed PCI. The label carries a boxed warning that the medicine can cause significant, sometimes fatal, bleeding.
Also called Effient
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 613391. MeSH descriptor D000068799 is Prasugrel Hydrochloride, the salt, so it is a broad match; MeSH has no descriptor for prasugrel itself. UNII G89JQ59I13 is the UNII of prasugrel hydrochloride, the salt the label names, and is a broad match. The label read is the Cosette Pharmaceuticals, Inc. label for Effient, application NDA022307, effective 2022-09-07 in openFDA; a newer label may exist outside openFDA. Generic prasugrel labels were not read. This page records label indications, the first line of the boxed warning and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 27 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 27
- Phase 3 or 4
- 25
- Recruiting
- 2
- Regulatory decisions
- 0
| Phase | Recruiting | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|---|
| Phase 2 | 0 | 1 | 0 | 0 | 1 |
| Phase 2/3 | 0 | 1 | 0 | 0 | 1 |
| Phase 3 | 1 | 4 | 0 | 1 | 6 |
| Phase 4 | 1 | 14 | 2 | 2 | 19 |
| All phases | 2 | 20 | 2 | 3 | 27 |
Conditions these trials study
- Acute coronary syndrome
- Heart attack (myocardial infarction)
- Coronary artery disease
- ST-elevation heart attack (STEMI)
- Arrhythmia (heart rhythm problems)
- Atrial fibrillation (AF)
- Angina pectoris
- Brain aneurysm (intracranial aneurysm)
- Unstable angina
Sponsors with the most trials
- LMU Klinikum
- University of Florida
- Amsterdam UMC, location VUmc
- Assistance Publique Hopitaux De Marseille
- Azienda USL Reggio Emilia - IRCCS
About this drug
- Level
- Substance
- Mechanism
- The label says an active metabolite of prasugrel binds irreversibly to the P2Y12 class of ADP receptors on platelets, which inhibits platelet activation and aggregation.
Classification codes
-
G89JQ59I13 -
D000068799
Claims and evidence
Context People for whom the US label of prasugrel (Effient) lists an indication: acute coronary syndrome managed with percutaneous coronary intervention
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The label passages read do not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Patients with unstable angina or non-ST-elevation myocardial infarction who are to be managed with percutaneous coronary intervention
- Patients with ST-elevation myocardial infarction managed with primary or delayed percutaneous coronary intervention
- Excluded
- None stated
The US label of Effient (prasugrel), in the Cosette Pharmaceuticals, Inc. version dated 2022-09-07 in openFDA, lists the medicine to reduce the rate of thrombotic cardiovascular events, including stent thrombosis, in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI): patients with unstable angina or non-ST-elevation myocardial infarction, and patients with ST-elevation myocardial infarction managed with primary or delayed PCI. The label carries a boxed warning that the medicine can cause significant, sometimes fatal, bleeding.
Applies to Recipient not specified People for whom the US label of prasugrel (Effient) lists an indication: acute coronary syndrome managed with percutaneous coronary intervention
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the first line of the boxed warning and the mechanism sentence were read; the rest of the boxed warning, contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA's version may be older than the current label. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (6)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2022-09-07
- Source state
- Current
- Version fingerprint
f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.1 Acute Coronary Syndrome
- How it applies
- Label passage quoted in the research quote table (LB-05).
- Retrieved
- Source effective date
- 2022-09-07
- Source state
- Current
- Version fingerprint
f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.1 Acute Coronary Syndrome, unstable angina or NSTEMI
- How it applies
- Label passage quoted in the research quote table (LB-06).
- Retrieved
- Source effective date
- 2022-09-07
- Source state
- Current
- Version fingerprint
f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.1 Acute Coronary Syndrome, STEMI
- How it applies
- Label passage quoted in the research quote table (LB-07).
- Retrieved
- Source effective date
- 2022-09-07
- Source state
- Current
- Version fingerprint
f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], sentence 1
- How it applies
- Label passage quoted in the research quote table (LB-08).
- Retrieved
- Source effective date
- 2022-09-07
- Source state
- Current
- Version fingerprint
f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20220907.
- Retrieved
- Source effective date
- 2022-09-07
- Source state
- Current
- Version fingerprint
f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
EFFIENT
No label from the application holder was found in the openFDA label dataset for application NDA022307. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists acute coronary syndrome managed with percutaneous coronary intervention as an indication: Acute coronary syndrome
Applies to Recipient not specified People for whom the US label of prasugrel (Effient) lists an indication: acute coronary syndrome managed with percutaneous coronary intervention
The US label of Effient (prasugrel), in the Cosette Pharmaceuticals, Inc. version dated 2022-09-07 in openFDA, lists the medicine to reduce the rate of thrombotic cardiovascular events, including stent thrombosis, in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI): patients with unstable angina or non-ST-elevation myocardial infarction, and patients with ST-elevation myocardial infarction managed with primary or delayed PCI. The label carries a boxed warning that the medicine can cause significant, sometimes fatal, bleeding.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the first line of the boxed warning and the mechanism sentence were read; the rest of the boxed warning, contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA's version may be older than the current label. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists unstable angina managed with percutaneous coronary intervention as an indication: Unstable angina
Applies to Recipient not specified People for whom the US label of prasugrel (Effient) lists an indication: acute coronary syndrome managed with percutaneous coronary intervention
The US label of Effient (prasugrel), in the Cosette Pharmaceuticals, Inc. version dated 2022-09-07 in openFDA, lists the medicine to reduce the rate of thrombotic cardiovascular events, including stent thrombosis, in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI): patients with unstable angina or non-ST-elevation myocardial infarction, and patients with ST-elevation myocardial infarction managed with primary or delayed PCI. The label carries a boxed warning that the medicine can cause significant, sometimes fatal, bleeding.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the first line of the boxed warning and the mechanism sentence were read; the rest of the boxed warning, contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA's version may be older than the current label. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists non-ST-elevation myocardial infarction managed with percutaneous coronary intervention as an indication: Non-ST-elevation heart attack (NSTEMI)
Applies to Recipient not specified People for whom the US label of prasugrel (Effient) lists an indication: acute coronary syndrome managed with percutaneous coronary intervention
The US label of Effient (prasugrel), in the Cosette Pharmaceuticals, Inc. version dated 2022-09-07 in openFDA, lists the medicine to reduce the rate of thrombotic cardiovascular events, including stent thrombosis, in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI): patients with unstable angina or non-ST-elevation myocardial infarction, and patients with ST-elevation myocardial infarction managed with primary or delayed PCI. The label carries a boxed warning that the medicine can cause significant, sometimes fatal, bleeding.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the first line of the boxed warning and the mechanism sentence were read; the rest of the boxed warning, contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA's version may be older than the current label. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists ST-elevation myocardial infarction managed with primary or delayed percutaneous coronary intervention as an indication: ST-elevation heart attack (STEMI)
Applies to Recipient not specified People for whom the US label of prasugrel (Effient) lists an indication: acute coronary syndrome managed with percutaneous coronary intervention
The US label of Effient (prasugrel), in the Cosette Pharmaceuticals, Inc. version dated 2022-09-07 in openFDA, lists the medicine to reduce the rate of thrombotic cardiovascular events, including stent thrombosis, in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI): patients with unstable angina or non-ST-elevation myocardial infarction, and patients with ST-elevation myocardial infarction managed with primary or delayed PCI. The label carries a boxed warning that the medicine can cause significant, sometimes fatal, bleeding.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the first line of the boxed warning and the mechanism sentence were read; the rest of the boxed warning, contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA's version may be older than the current label. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 1
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.
Registry trials 27
Record details
- Record id
cardio:prasugrel- Content hash
5950f34e37898707d193b68076622cc568f78e299a73cfb8e37f8b8013ecec24